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The biomaterial component of a tissue engineered device has been shown 
to enhance the immune response to a co-delivered model shed antigen.  The 
purpose of this research was to investigate in vivo the differential level of the 
immune response toward different forms of the biomaterial.  A model shed 
antigen, ovalbumin (OVA), was incorporated into polymeric biomaterial carriers 
made of 50:50 poly(lactic-co-glycolic acid) (PLGA) in the form of microparticles 
(MP) or scaffolds (SC).  These MP and SC biomaterial carrier vehicles with 
incorporated antigen were then injected or implanted, respectively, into C57BL6 
mice to investigate the differential level of the immune response towards OVA 
controlled release from PLGA MP and PLGA SC.  For each polymeric carrier, the 
resulting time-dependent systemic humoral immune response towards the 
incorporated OVA, the OVA-specific IgG concentration and isotypes (IgG2a or 
IgG1, indicating a predominant Th1 or Th2 response, respectively) were 
determined using ELISA.  To assess the differential level of the immune response 
depending on the form of PLGA, the total amounts of polymer and OVA 
delivered were kept constant as well as the release rate of OVA.  The in vitro 
protein release kinetics were studied for both PLGA microparticles and PLGA 
scaffolds to examine the release rate of OVA from the polymeric carriers.   
The level of the humoral immune response was higher and sustained for 
OVA released from PLGA SC which were implanted with associated tissue 
damage, and lower and transient when the same amount of polymer and OVA 
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were delivered from PLGA MP, which were minimally invasively delivered by 
injection.  This immune response was primarily Th2 helper T cell-dependent as 
exemplified by the predominance of IgG1 isotype, although for the strong 
adjuvant, Complete Freund’s adjuvant (CFA), and PLGA SC carriers the anti-
OVA IgG2a isotype levels were also significant, potentially indicating both a Th2 
and Th1 response.   
The PLGA SC and PLGA MP exhibited similar protein release kinetics, 
releasing similar amounts of OVA at each time point.  Each carrier incubated 
contained the same ratio of OVA to polymer.  In vitro protein release kinetics 
experiments suggest that the rate of release of OVA from PLGA SC and PLGA 
MP was similar, and therefore the enhanced immune response induced by PLGA 
SC is most likely due to ‘danger signals’ from implantation which primed the 
system for an enhanced immune response and not from a difference in 














Tissue engineering is an emerging multidisciplinary field involving biology, 
medicine, and engineering to revolutionize the way patients are treated by restoring, 
maintaining, or enhancing tissue and organ function.   Tissue engineering devices usually 
consist of a polymeric biomaterial component as well as associated cells or biomolecules, 
such as proteins.  These transplanted cells or biomolecules can be recognized as foreign 
by the host’s immune system depending on the cell source (allo- or xenogeneic), which 
stimulates an antigen-specific immune response.  The biomaterial may trigger a non-
specific inflammatory response including the recruitment and activation of antigen 
presenting cells such as dendritic cells and macrophages.  The biomaterial component has 
been previously shown to act as an adjuvant in the enhancement of the immune response 
towards to the cellular component of a tissue engineered construct.  The hypothesis of 
this research is that biomaterials in the form of scaffolds, which are implanted with 
associated tissue damage, induce a higher level of immune response to associated co-
delivered antigen as compared to biomaterials in the form of microparticles, which are 









Specific Aim 1:  Determine the formulation necessary to maintain a common ratio of 
OVA: polymer dose for both PLGA MP and PLGA SC carrier vehicles.  A ratio of 1.075 
mg OVA/mg polymer was formulated to keep the same ratio of OVA: polymer for both 
the PLGA MP and PLGA SC carrier vehicles.   A double-emulsion solvent-extraction 
technique with a polyvinyl alcohol coat allowed for the controlled encapsulation of OVA 
into the PLGA MP.  Ovalbumin was directly incorporated into PLGA SC in the 
commonly used solvent casting particulate leaching technique. 
 
Specific Aim 2:  Study the in vitro protein release kinetics of OVA from both PLGA MP 
and PLGA SC to insure a constant release rate for both carrier vehicles.  The in vitro 
release kinetics of OVA into PBS from OVA-loaded PLGA MP and PLGA SC were 
evaluated over 28 days.   
 
Specific Aim 3:  Assess the differential level of the enhancement in the immune response 
towards OVA when it is controlled released from PLGA MP or PLGA SC.   To 
investigate the differential level of the enhancement of the humoral immune response 
towards OVA controlled release from PLGA MP or PLGA SC, the total amount of 
polymer and OVA delivered (1.075 mg OVA/mg PLGA) was kept constant as well as the 
release rate of OVA from these two vehicles.  The controlled release of OVA from the 
carriers then allowed testing of the hypothesis that a differential level of biomaterial 
adjuvant effect will be observed in the immune response towards associated antigen 
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depending on the form of the carrier vehicle, which is proportional to the extent of tissue 
damage associated with its insertion in agreement with the ‘danger’ model of immunity.  
In the serum of C57BL/6 mice receiving these OVA carrier vehicles, the anti-OVA total 
IgG concentrations and isotypes were determined in order to study the differential level 






























 Across the United States, an average of seventeen men, women, and children die 
every day due to lack of sufficient numbers of organ donors.  According to the United 
Network for Organ Sharing (UNOS), currently there are over 85,000 patients waiting for 
organs in the United States alone, with 58,000 of these patients needing kidneys [1].  
Every twelve minutes another name is added to the growing organ transplant wait list due 
to injury, disease, or autoimmune disorders irreversibly damaging organs.    
Tissue engineering introduced an alternative to waiting for appropriate organ 
transplants in the 1970’s by the concept of applying a combination of polymers (natural 
or synthetic), cells, and biomolecules for the regeneration, repair, or modification of 
damaged tissues or organs.  Tissue engineering seeks to regenerate tissues with methods 
other than conventional medicines and drug therapies.  Included in tissue engineering is 
the development of cell lines and tissues for the intent of restoring function and 
physiology lost due to damaged tissue or organs.  A large amount of research focuses on 
restoring function through the use of cell therapies derived from autologous cells, cells 
from an established cell line, stem cells, or genetically modified cells [2,3].  To expand 
the possible sources of cells, cells from human donors (allografts) [4] or from other 
animals (xenografts) [5] are being explored, however there is still the concern of 
immunological rejection as in organ transplantation.  These modified cells can then be 
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seeded into a three-dimensional device component such as a scaffold, matrix, or 
membrane, in order to regenerate damaged tissue.  For the tissue engineered construct to 
be successful in regenerating tissue, the cells must be viable and able to carry out their 
metabolic functions within the matrix.  The tissue engineered device allows stimulation, 
directly or indirectly, of cells into a specific activity [6].  Also, the biomaterial 
component, typically a polymer, must sustain long-term structural and functional 
properties in order to endure the harsh physiological environment.  Along with this harsh 
physiological environment is the potential immune response towards the tissue 
engineered construct in vivo due to the cellular component which may be of allogeneic or 
xenogeneic origin.  An inflammatory response will typically be directed against the 
biomaterial component of the construct while a specific immune response may be 
directed against incorporated foreign cells of either allogeneic or xenogenic origin.  In 
order to be successful and fully integrate into neighboring tissue, a tissue engineered 








 Biomaterials used in tissue engineering may be of either natural or synthetic 
origin.  Synthetic biomaterials [e.g., poly(α-hydroxy acid) family of polymers [e.g., 
poly(lactic-co-glycolic acid) (PLGA)]] are typically biodegradable, temporary three-
dimensional scaffolds which allow cells to attach and eventually grow and differentiate in 
a preferred manner while depositing their own natural extracellular matrix as the 
biomaterial degrades.  This property of biodegradation makes PLGA scaffolds attractive 
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for gradually regenerating tissues, yet the PLGA scaffold may only be used as a 
temporary implant as a result [7].  Natural biomaterials include protein and 
polysaccharide polymers such as collagen, fibrin, elastin, alginate, chitosan, and 
hyaluronic acid.  These biomaterials are similar in nature to the host tissue and have less 
toxicity.  However, they are also quite immunogenic and structurally complex, making 
them difficult to manufacture [7]. 
Scaffolds may also be used as a method of gradually delivering growth factors to 
encourage new cell growth and direction [8].  The biomaterial scaffold will eventually 
degrade and be replaced by a cell-derived extracellular matrix, resulting in the formation 
of natural tissue.  Biomaterials may also be fabricated in other forms besides scaffolds 
such as injectable systems for cell printing (assembling cells in a pre-defined pattern onto 
a biomedical construct) and injectable polymeric microparticles.  These injectable 
biomaterials allow for great ease in implantation and less complications as observed with 
invasive surgeries.  Overall, a biomaterial will influence surrounding natural tissue as 
well as be influenced by the tissue to degrade over time and be replaced by the host 
natural tissue [8]. 
The advantage of using biomaterials in tissue engineering is the ability to restore 
function and physiology lost due to damaged tissue or organs and the ability to transplant 
altered cells into specific locations, including immunoprivileged sites.  These cells can be 
manipulated, unlike with transplant organs, to enhance a specific function or to reduce 
immunogenicity so that a transplant is more successful in its ability to integrate into the 
host tissue.  Altered cells for transplantation may also be cryopreserved for off the shelf 
availability and joined with a combination of other cells in a biomaterial scaffold to 
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enhance a specific function [9].  Since the cells may be manipulated in order to decrease 
immunogenicity, allogenic and xenogenic cells may be used for this form of tissue 
engineering, potentially offering unlimited cell sources.  In reality, these transplanted 
cells will induce an immune response and may cause severe complications upon 
implantation.  More research is needed to find a method to truly immunoisolate these 
foreign cells from the host defense system and thereby avoid implant rejection. 
 For each specific application, a biomaterial must be considered for its 
composition, mechanical properties, porosity, degradation rate, reproducibility, 
biocompatibility, sterilizability, and shelf-life.  It is important to consider such properties 
as the topography for cell attachment and migration or differentiation.  Most scaffolds are 
porous so that surrounding tissue may infiltrate the scaffold and begin to regrow [10].  
Polymers such as nylon and polyester are commonly used as sutures and artificial blood 
vessels due to their resilient strength.  Biodegradable polymers are resilient and easy to 
fabricate, yet they are also not very strong and will deform with time as they degrade.  As 
a polymer degrades, it will release degradation products that will change the acidity of 
the local environment, resulting in changes in homeostasis [7]. Metals, such as titanium 
and stainless steels, are used as bone plates and joint replacements due to their strong and 
ductile mechanical properties. Stainless steels were used as early joint replacement 
prosthesis components and found to be inadequate in their fatigue strength, allowing 
bending and breaking of the device with stress over time.  These metals may be 
chemically passivated in order to increase biocompatibility with the host, yet the 
properties of the metal may change with this passivation such as the hardness of the 
metal. A major concern with metals as biomedical implants is their ability to corrode 
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upon removal of this passivation coating.  Ceramics, such as calcium phosphates and 
hydroxyapatite, are biocompatible and are used for orthopedic implant parts [7].  They 
are well tolerated by the body, yet they are brittle and difficult to manufacture.   
 
 
Natural Biomaterials For Tissue Engineering 
 
 Natural biomaterials include such materials as protein polymers, polysaccharide 
polymers, and lipids.  Of these materials, collagen, chitin, and hyaluronic acid (HA) are 
the most commonly used for tissue engineering devices.  Advantages of natural materials 
include biofunctionality, biodegradablitiy, and less of an inflammatory response upon 
implantation into the host.  However the disadvantages include low mechanical 
properties, low stability, and complex processing [7, 11].   
 Natural biomaterials are biomimetic in that they are able to imitate the 
extracellular matrix of natural tissues.  Chitosan, manufactured from polysaccharide 
chitin found in crab shell, is often used for absorbable sutures as well as for skin and 
cartilage tissue engineering [12,13].   Chitosan fiber scaffolds with seeded chondrocytes 
are able to produce new extracellular matrix in a way similar to natural cartilage.  The 
randomly arranged chitosan fibers are able to distribute the strain and allow for the 
integration of new cartilage [13].  These scaffolds offer promise in using natural 
biomaterials for the repair of defects in articular cartilage as they have the appropriate 
structure and the desired composition, mechanical properties, and durability similar to 
articular cartilage in vivo.  Chitosan fiber scaffolds have proven to be more successful for 
this area of tissue engineering versus foams and hydrogels which do not meet these 
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physical and mechanical needs [13].  However, chitosan is highly immunogeneic and 
there are some concerns about its toxicity. 
 Collagen, a family of fibrous insoluble proteins, is another promising natural 
biomaterial which is used for skin and cartilage tissue engineering, heart valves and 
vascular grafts, orthopedic applications, and drug delivery.  Collagen is commonly used 
for such medical purposes as replacing ligaments due to its mechanical strength [14] and 
for facial dermal repair [14].  Studies have suggested that collagen with immobilized 
heparin prevents surface thrombus formation, making collagen safe and efficient for 
vascular grafts [16].  However, it is still significantly immunogeneic.  Collagen with 
incorporated human fibroblasts exhibits high mechanical strength, which makes it a 
useful seeded scaffold for potential use in an artificial heart [17].  One of the most 
popular uses of collagen is for cartilage tissue engineering.  As collagen scaffolds 
gradually degrade, they form homogenous cartilage much like the natural host cartilage.  
Cartilage tissue engineering efforts have focused on combining collagen with synthetic 
polymers in order to increase the mechanical properties of a scaffold as well as to 
increase cell-seeding of chondrocytes [18].   
 Hyaluronic acid (HA) is a component of the extracellular matrix of embryonic 
mesenchymal tissue which is often used for dermal wound healing applications as well as 
bone tissue engineering.  When fibronectin (FN) is combined with HA in collagen 
scaffolds, fibroblasts are encouraged to migrate into the scaffolds and stimulate wound 
healing.  The HA component of the scaffold will enhance wound healing and tissue 
regeneration, even in areas where scar tissue may block natural wound healing [19].  
Hyaluronic acid in the form of hydrogels is unique in its wound healing and angiogenesis 
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ability.  As a natural polymer, it is easily manufactured and modified, as well as 
hydrophilic and biodegradable.  Hyaluronic acid is also nonadhesive, a required property 
for vascular grafts [20].   There is some question about the long-term mechanical 
properties of HA.  Research is currently underway to strengthen HA by the addition of 
other materials or chemicals.   
Two types of biomaterials may also be combined in a scaffold in order to form a 
device with multiple properties of the individual components.  For example, 
polysaccharide hybrid materials for cartilage tissue engineering scaffolds can be 
composed of alginate and chitosan fibers to allow for enhanced chondrocyte adhesion 
[21].  The combination of these two polymer fibers allows for enhanced adhesion of 
chondrocytes as well as the maintenance of cellular structure.  In the area of bone tissue 
engineering, hydroxyapatite/collagen (HAC) scaffolds mimic the extracellular matrix of 
bone.  The collagen component allows for natural-like apatite formation [22]. Agarose 
combined with fibronectin has been used as conduits to repair short gaps in peripheral 
nerves, and recently for large gaps [23].  These conduits allow growth of Schwann cells 
and fibroblasts by contact guidance.  In deciding what material to use it is important to 
consider the intended application of the device and whether the materials used are 
appropriate.     
 
Synthetic Biomaterials For Tissue Engineering 
 
Of the synthetic biomaterials (including polymers, metals, ceramics, and glass) 
polymers are most commonly used in tissue engineering.  Much research focuses on the 
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use of polymers from the poly(α-hydroxy acid) family, which are thermoplastic aliphatic 
polymers with many desirable properties for tissue engineering constructs such as their 
ability to biodegrade, their biocompatibility, and their relatively good processability.  
Disadvantages include immunogenecity, poor mechanical properties, and acidic 
degradation products which may effect homeostasis.  Common homopolymers in this 
family are poly(L-lactic acid) (PLLA) and poly(glycolic acid) (PGA) which may be 
joined in various molar ratios to form the copolymer poly(DL-lactic-co-glycolic acid) 
(PLGA).   
The copolymer PLGA is a biodegradable polymer which undergoes non-
enzymatic bulk degradation by hydrolysis of the ester linkages in the backbone of the 
polymer [24]. The degradation rate of PLGA is dependent to an extent on the molar ratio 
of lactic to glycolic acid.  The degradation time of PLGA can be controlled from weeks 
to over a year by varying the ratio of monomers.  For example, increasing glycolic acid, 
the hydrophilic component of the copolymer, increases the biodegradation rate [25].  As 
the PLGA biodegrades, lactic acid is naturally metabolized in the tricarboxylic acid cycle 
and then eliminated from the body in the form of water and carbon dioxide removed 
through respiration [26]. Glycolic acid may also follow this cycle or be excreted 
unmodified from the body as water and carbon dioxide.  During biodegradation of 
PLGA, it is important that these acidic degradation products are removed from the body 
to maintain homeostasis [27]. 
The strong interest in biodegradable polymers such as PLGA is that they do not 
elicit permanent chronic foreign-body reactions, as they will be gradually absorbed by the 
host.  They also are able to regenerate tissues through the interaction of their 
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biodegradation with immune cells.  However, even with this appeal, the biodegradable 
polymer implants release acidic degradation products which cannot be eliminated quickly 
enough from the body, resulting in changes in homeostasis.  A solution to this problem 
would be to allow for a slower release of degradation products versus a burst release so 
that the products could be timely metabolized.  The development of new biodegradable 
polymers is a research challenge as they must be biocompatible and release low-toxicity 
degradation products. 
The poly (alpha-hydroxy acid) family is commonly used for a variety of 
biomedical purposes [28] including sutures, drug delivery devices, orthopedic fixation 
devices, as well as tissue engineered blood vessels, and nerve regeneration channels.   
The biodegradable polymer poly(L-lactic acid) (PLLA) has a high tensile strength and 
low elongation which allows it to have a high modulus suitable for load-bearing 
applications such as bone fracture fixation.  Poly(glycolic acid) (PGA) was first used as 
resorbable sutures, and then became material for meshes and surgical products [29]. A 
limitation of these sutures is that they lose their mechanical strength at 2 to 4 weeks after 
implantation.  Sponge tubes made of PGA-collagen for nerve regeneration show more 
promise than the composite tubes in maintaining structural integrity for neuronal support 
[30].  The copolymer PLGA is commonly used for cartilage tissue engineering due to its 
ease in incorporating chondrocytes and supporting their differentiation into an 
appropriate phenotype [31].  Many studies focus on using PLGA in the form of 
microparticles for drug or growth factor delivery.  An attractive use of PLGA in tissue 
engineering is the potential to transplant pluripotent stem cells inside PLGA 
microparticle beads to stimulate tissue regeneration [32]. 
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There is also a motivation to manufacture biomaterial surfaces to which proteins 
will not adhere.  Polyethylene oxide (PEO) aids in making a biomaterial more 
biocompatible by reducing non-specific protein adherence to biomaterials [33,34].  These 
biomaterials are able to resist leukocyte adhesion, therefore inducing less of an 
inflammatory response.  However, fibrous encapsulation will still occur due to 
macrophages at the implant site.  Hydrophilic and anionic substrates allow for decreased 
rates of macrophage adhesion on biomaterial surfaces [35].   
The decision of which biodegradable material to use for an application should 
consider the kinetics of degradation as well as the mechanical properties.  For a material 
to be more susceptible for degradation so that the natural tissue will replace the scaffold, 
bonds need to be susceptible to cleavage so that enzymes may gradually digest the 
biomaterial in vivo.  It is also important that the degradation products be nontoxic [36].   
Another advantage of biodegradable polymers is the ability to manufacture the polymers 
in different geometries and different sizes for tissue regeneration as well as the 




In 2003 it was suggested that the term biocompatibility should be based on the 
application of the biomaterial versus the composition of the material [6].  Previously the 
definition had been based on the ability of a material to perform with the appropriate 
response in a specific application, and considered mainly only the biological safety of the 
material.  How the biomaterial performs should be included in the definition, not just that 
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it is of a certain material.  It is important to recognize that the host response to the 
material will vary and some materials are not as applicable and efficient in certain 
situations as others.  Biomaterials today are varied in their applications and responses so 
that a new definition of biocompatibility must be considered [6].   
Long-term implanted biomaterials, such as titanium, cobalt-chromium alloys, 
platinum, carbon, alumnia, silicone, polytetrafluoroethlyene (PTFE), polyester, 
polymethylmethacrylate (PMMA), and polyethylene (PE), are used as such due to their 
mechanical properties as well as ability to resist corrosion and degradation.  For these 
long-term implants, the importance is the outlasting mechanics and relatively low 
reactivity [6,7].  Although some of these long-term implants have been coated with 
surface coatings, these coats can be subjected to degradation (i.e. by the changing pH of 
the local environment due to metabolic products), rendering then more likely to induce an 
inflammatory response. Also, the corrosion products may elicit an adverse biological 
reaction in the host. To control this corrosion, researchers have used noble metals (i.e. 
gold, silver, and platinum) which exhibit good corrosion resistance.  However, these are 
costly and have poor mechanical properties.   Therefore most research focuses on 
passivation of mechanically strong biomaterials.  Biocompatibility should be thought of 
as a two way street with the material affecting the host either systemically or locally and 
the host affecting the degradation of the material as well.  The biocompatibility of a tissue 
engineered device is described as the ability of a scaffold, matrix, or membrane to 
support cellular activity in order to optimize tissue regeneration without any damaging 
effects to these cells or the host either locally or systemically [6].   
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It would be ideal to make a biomedical polymer that is relatively unreactive and 
non-toxic.  However, no biomaterial is inert and unreactive when in contact with the host 
environment.  Most biomaterials will exhibit some thrombogenic and inflammatory 
properties.  
 
Inflammatory Response to Implanted Biomaterials 
 
Tissue damage and changes in homeostasis occur with the implantation, insertion, 
or injection of a biomaterial, resulting in damage to connective and adipose tissue and the 
release of proteins from these damaged tissues into the surrounding area.  Injury to tissue 
caused by the insertion of a biomaterial leads to a tissue response in the form of 
inflammation, wound healing, and foreign body response [37].  The extent and duration 
of the host tissue response will depend on the implant procedure as well as the physical 
and chemical properties of the biomaterial implanted.  Many events occur during the host 
response of inflammation and wound healing after an injury, and may follow the 
sequence of acute inflammation, chronic inflammation, granulation tissue formation, 
foreign body reaction, and fibrosis [37].   
After a biomaterial is implanted, inflammation occurs in order to contain any 
harmful agent at the site of injury as well as to begin regenerating natural parenchymal 
cells at the site.  Blood proteins, cells, and plasma fluid may leave damaged blood vessels 
through exudation, stimulating cellular responses and chemical factors for mediating 
inflammation [37].  At this time thrombosis may occur due to an accumulation of 
activated platelets, forming a blood clot which aids in immune cell migration.  Platelets 
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adhere to collagen exposed during blood vessel injury and form a thrombus by the 
binding of plasma fibrinogen and von Willebrand Factor to the integrin alpha(IIb)beta(3) 
[38].  Activated platelets express P-selectin which will later mediate leukocyte rolling to 
the injury site [39].  They also express platelet-derived growth factor (PDGF) and 
transforming growth factors (TGF B1 and B2) from their granules, activating 
macrophages and fibroblasts to migrate to the injury site and initiate wound healing [37].  
Platelet adhesion to biomaterial surfaces may be mediated by platelet glycoprotein 
IIb/IIIa as well as through the GP IIb-vWF interaction.  Platelet activity is studied to 
produce a non-thrombogenic tissue engineered construct.  If a biomaterial induces 
thrombosis platelets will be removed from circulation at a rapid rate, resulting in platelet 
consumption.  In a study of the importance of PDGF in regulating wound healing, 
transgenic mice with PDGF-D showed increased macrophage recruitment and 
angiogenesis as compared to control mice [40]. 
Acute inflammation occurs over minutes to days and is important for the 
emigration of leukocytes, mainly neutrophils, from the blood vessels to the implantation 
site [37].    Leukocytes migrate by “rolling” along the endothelium, a process which is 
assisted by adhesion molecules and chemotactic stimuli. Selectins, such as L-selectin 
expressed on neutrophils, initiate primary interaction between the endothelium and 
leukocytes, resulting in “rolling” of the leukocytes along the venous wall [41].  This 
rolling induces leukocyte activation due to contact with activating molecules (e.g., 
interleukin 8) resulting in an upregulation of the functional activation of beta 2-integrins 
(CD11/CD18) which interact with the counter receptor ICAM-1 on the endothelium, 
leading to a secondary, tighter adhesion between leukocytes and the endothelium [42].   
 17
After migration to the implantation site, the leukocytes initiate phagocytosis by 
releasing cytokines, proteolytic enzymes, and reactive oxygen intermediates.  At the same 
time, monocytes are stimulated to migrate in response to TGF-beta and monocyte 
chemoattractant protein-1, and will differentiate into macrophages at the injury site [43].  
Macrophages work alongside leukocytes in the phagocytosis of bacteria, debris, or 
foreign particles as well as initiate wound healing by releasing a variety of growth 
factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) to stimulate angiogenesis [40].   
During phagocytosis, neutrophils and macrophages must first recognize and bind 
to harmful agents which have been coated with opsonins (serum factors such as 
immunoglobulin G (IgG), complement-activated fragment C3b, and fibrinogen), engulf 
the agent, and finally degrade it [37, 44, 45, 46]. Sometimes, however, the biomaterial is 
too large for this engulfment and “frustrated” phagocytosis occurs so that phagocytes 
resort to releasing enzymatic products in an attempt to degrade the foreign material [37].   
Macrophages will secrete different cytokines and growth factors depending on the 
particular opsonins coating a biomaterial.  This also controls the ability of the fibroblasts 
to proliferate as different cytokines will have different influences on fibroblast growth 
[46].  Protein adsorption on a biomaterial surface produces different levels of 
macrophage cytokines IL-1 beta, IL-6, and TNF-alpha, suggesting that macrophage 
activation is indeed dependent on the type of polymer as well as the type of adsorbed 
proteins on the polymer [47]. 
Chronic inflammation develops with the prolonged presence of inflammatory 
stimuli, macrophages, and lymphocytes as well as the regeneration of blood vessels and 
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connective tissue [37].  Macrophages are able to process foreign antigens and present 
them to other immune cells to stimulate an adaptive immune response towards the 
specific antigen.  They also are able to secrete important growth factors for wound 
healing such as fibroblast growth factor (FGF) for the proliferation of fibroblasts, tumor 
necrosis factor (TNF), platelet-derived growth factor (PDGF), and vascular endothelial 
growth factor (VEGF) for the regeneration of blood vessels. Growth factors from 
macrophages will encourage cells to proliferate, migrate, and differentiate as well as 
stimulate tissue remodeling [37, 40].   
As little as four days after biomaterial implantation, fibroblasts and endothelial 
cells may begin to proliferate and form granulation tissue, a sign that wound healing is 
initiated.  Angiogenesis occurs when the endothelial cells mature and form an organized 
layer within capillary tubes [40] and new tissue is formed by the migrating fibroblasts 
[48,49]. Macrophages at the site continue to release growth factors and cytokines, for 
example PDGF, VEGF, and FGF [48].  The new tissue is a matrix for macrophages and 
fibroblasts to migrate and initiate tissue regeneration and remodeling.  Eventually the 
tissue will be remodeled and cross-linked collagen with a high tensile strength, mainly 
collagen III, will be formed on this matrix [48, 49].   Fibroblasts will continue to 
proliferate and differentiate into myofibroblasts as they manufacture new collagen.  This 
fibroblast proliferation is controlled by a complex signaling pathway involving TNF-beta 
as well as epidermal growth factor (EGF) [49].  Once the injury site is cleared of harmful 
agents, fibroblasts will proliferate at the injury site, depositing new tissue, and initiate 
wound closure [48].  
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The foreign body response, the last stage of the wound healing process, is 
dependent upon the topography of the biomaterial [37].  A smooth surface may attract 
minimal macrophages while a rough surface will also result in the formation of foreign 
body giant cells (fused monocytes and macrophages) (FBGC).  The macrophages are 
activated by both chemical and physical cues from the biomaterial [50] and foreign body 
giant cells may stay on the surface of an implant throughout its in vivo use.  The final 
phase of wound healing is the fibrous encapsulation of the biomaterial, isolating it from 
the rest of the host.  There is an interest of the effect of this fibrous barrier on the 
diffusion of nutrients and drugs.  It is important to keep any implanted cells within a 
biomaterial alive and able to receive nutrition as well as discard metabolic waste [51].  
The amount of encapsulation also depends on the form of the biomaterial and the 
intensity of the implantation (for example injection versus surgical implantation).  Small-
diameter microfiber implants do not become encapsulated after subcutaneous 
implantation, although large-diameter fibers (5.9 micron) are encapsulated [52].  It is 
believed that the larger diameter fibers have a more pronounced dead space area between 
collagen fibers which attracts the infiltration of inflammatory cells into the space, 
stimulating fibrous encapsulation.  The overall wound healing is highly dependant on 
adequate blood supply, the ability to receive nutrition, and the ability of the cells at the 
site to proliferate and differentiate.   
Many studies have focused on reducing the host inflammatory response towards a 
biomaterial and thus increasing its biocompatibility.  There is a motivation to decrease 
the amount of macrophages and foreign body giant cells which release harmful 
degradative enzymes towards the biomaterial.  For example, polyurethanes with modified 
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surfaces containing silicone can alter and decrease macrophage adhesion, improving the 
biostability of polyurethane [53].  To inhibit FBGC, diacylglycerol kinase inhibitor 
R59022 has been discovered as a potent inhibitor of macrophage and monocyte fusion to 
form FBGCs.  On the other hand, alpha-tocopherol stimulates FBGC formation [54].  As 
mentioned before, different surface properties of a biomaterial may alter the degree of 
macrophage and FGGC formation at the surface.  For example, an interpenetrating 
polymer network composed of polyacrylamide and poly(ethylene glycol) restricts cell 
adsorption while N-(2 aminoethyl)-3-aminopropyltrimethoxysilane promotes cell 
adhesion.  This difference in surface chemistry controlled FBGC formation and 
macrophage fusion so that the interpenetrating polymer network did not form FBGCs 
[55].  Specifically, the copolymer PLGA has shown good biocompatibility with little 
FBGC formation at its surface.  The two components of PLGA, PGA and PLLA, have 
shown to cause little inflammatory response (a scarce number of monocytes and 
leukocytes at the site) as biodegradable pins and screws for the fixation of bone factures 
[56], and in fact the copolymer PLGA shows little inflammatory response in vivo, making 
it a biocompatible polymer [57].   
 
 
Innate and Adaptive Immunity 
 
In order to create a tissue engineered device with incorporated cells (such as 
allogeneic or xenogenic cells) which will fully integrate into host tissue without rejection, 
it is necessary to understand both the innate immunity towards the implant (typically 
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considered the inflammatory response) as well as the adaptive immunity towards the 
transplanted cells.  Innate and adaptive immunity are not independent processes and it is 
vital to understand their interconnections in order to learn how to engineer the immune 
response and allow a device to evade this response, thereby integrating into the host 
tissue successfully. 
          Within hours of infection due to a pathogen or injury due to an implantation, innate 
immunity takes effect and stimulated phagocytes and natural killer cells arrive at the site 
of inflammation.  Innate immunity is the first line of defense against foreign materials 
(e.g., pathogens or biomaterials) and has physical barriers such as the epithelium as well 
as blood proteins such as complement, inflammatory molecules, and cytokines [58].  The 
innate immune response is largely mediated by phagocytes (such as neutrophils, 
macrophages, and natural killer cells) which engulf the foreign materials and release 
mediators such as reactive oxygen intermediates in an attempt to destroy them.  Innate 
immunity is responsible for recognizing microbes or other foreign materials such as 
biomaterials whereas adaptive immunity recognizes both microbes and non-microbal 
agents such as transplanted cells which are allo- or xenogeneic.  Unlike innate immunity, 
there is more diversity with adaptive immunity as well as B memory cells which can 
retain memory of an antigen.  The innate response to a foreign body, either a pathogen or 
an implanted biomaterial, is the same as the inflammatory response to biomaterials.    
        The innate immune system may recognize foreign agents through either 
evolutionary conserved structures belonging to pathogens or through opsonin proteins 
coating a foreign object. Once a foreign antigen is recognized as such by an antigen-
presenting cell (APC), the antigen is engulfed, processed, and then presented on the APC 
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to lymphocytes, a process which initiates adaptive immunity.  Adaptive immunity is 
responsible for clearance of antigens, cells, or pathogens and is composed of cellular 
immunity and humoral immunity.  Cellular immunity involves the clonal expansion of 
antigen specific T helper cells which will secrete cytokines for the activation of T and B 
cells to proliferate and differentiate.  During cellular immunity, cytotoxic T cells or 
natural killer cells are involved in direct killing of cells containing foreign antigen.  In 
humoral immunity B cells produce antigen specific antibody for the clearance of a 
pathogen [59]. 
       There are two different pathways for antigen presentation depending on where the 
antigen was derived.  Antigens in the extracellular environment (exogenous antigens) will 
be engulfed and processed by an APC and then presented in the direct pathway of antigen 
presentation, major histocompatibility complex (MHC) class II pathway. The host APCs 
in the MHC class II pathway present antigen to T helper cells via the CD4 molecule on 
the T cells.  MHC class II is expressed on mononuclear phagocytes, B cells, dendritic 
cells, endothelial cells, as well as thymic endothelium.  These complexes are responsible 
for binding antigen and presenting it to T cells.  They define self and each individual’s 
MHC molecules differ from the next.  Different MHC molecules also present different 
antigens.  During the second, indirect pathway of antigen presentation, or MHC class I 
pathway, antigens are processed from the cytosol (intracellular) and then presented by 
APCs to the CD8 molecule on cytotoxic T cells.  MHC I is expressed on nucleated cells 
as well as dendritic cells [58].  Cross-presentation of MHC molecules is also possible, 
providing immunity to viruses and tolerance to self.  There is new evidence that dendritic 
cells have an ability to process exogenous antigens into the MHC class I pathway [59]. 
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       The bridge between innate and adaptive immunity occurs when the innate immune 
system’s pattern recognition receptors (PRRs) located on phagocytotic cells recognize 
and bind pathogen associated molecular patterns (PAMPs). These PRRs, such as C-type 
lectins and Toll-like receptors, recognize pathogens as well as stimulate intracellular 
signaling which leads to the activation of the antigen presenting cells such that they are 
efficient at antigen presentation and T cell stimulation.  For example, the mannose 
receptor on macrophages binds certain sugar molecules on pathogens and toll-like 
receptor 4 (TLR4) stimulates intracellular signaling upon contact with lipopolysaccharide 
(LPS) by associating with CD14 on a macrophage [58, 60, 61].    
       During the MHC class II pathway of antigen presentation, a foreign antigen from the 
extracellular region is engulfed by an APC and degraded in the endocytotic vesicles 
within the cell which contain proteolytic enzymes.  After the antigen is degraded into 
peptide, MHC class II molecules, which are originally manufactured in the cell’s 
endoplasmic reticulum, fuse with the endocytotic vesicles to associate with the processed 
antigens inside the vesicles.  After fusion, they form an antigen-MHC class II complex 
which is transported to the cell surface to be presented by the APC to CD4+ T helper 
cells (Figure 2-1). During MHC class I antigen presentation, either pathogenic proteins or 
self-proteins which have mutated within the cell cytosol are processed in the cell 
proteasome and then transported to the endoplasmic reticulum where they fuse with 
MHC class I molecules.  After fusion, the antigen-MHC class I complex is transported to 







Shed antigen (surface molecules, secreted 































       Antigen-presenting cells, such as macrophages displaying the antigen-MHC 
complex, which have been activated during the innate immune response are the link 
between innate and adaptive immunity as they become efficient at stimulating the 
activation of T and B lymphocytes and the eventual production of antigen-specific 
antibodies (Figure 2-1).  In particular, dendritic cells are unique from all other APCs, as 
they are the only cells with the ability to stimulate naive T lymphocytes [63].  Once an 
APC has processed an antigen, it enters the lymphatic capillaries to travel to the lymph 
nodes where many naïve T lymphocytes are situated.  These T cells are formed in the 
thymus and travel to the lymph nodes to come into contact with the APC antigen-MHC 
complexes via the T cell receptor (TCR).  Each TCR is specific for a particular antigen-
MHC complex [58].  On a T cell, the co-receptor molecule CD4 will bind to specific 
parts of the MHC class II molecule.  During MHC class I antigen presentation, CD8 
binds the MHC class I molecule.  This T cell activation is also regulated by co-
stimulatory molecules such as CD80 and CD68 on APCS which bind to CD28 on T cells 
[58].  Once T cell activation has occurred, naïve T cells synthesize the autocrine growth 
factor interleukin-2 (IL-2) which stimulates the growth and differentiation of both CD4+ 
and CD8+ T cells.  Clonal expansion of the T cells occurs when the expression of the 
alpha chain of the IL-2 receptor is upregulated.  Eventually large numbers of antigen-
specific T cells are manufactured.  These T cells, either CD4+ or CD8+, will differentiate 
and mature.   The T helper cells will secrete IL-4 to stimulate B cell growth and IL-5 to 
stimulate B cell differentiation.  The cytokine INF-γ is responsible for activating 
macrophages and therefore inducing delayed hypersensitivity towards an antigen (Figure 
2-1).  The CD4+ T cells may be further divided into two classes of T helper cells: Th1, 
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which secrete cytokines that support cell-mediated immunity, and Th2, which secrete 
cytokines during humoral immunity [58, 59].   
       Naïve T cells are stimulated via IL-12 from macrophages to become Th1 cells.  Th1 
helper T cells activate macrophages to increase expression of MHC class I and MHC 
class II molecules by secreting interferon-γ (IFN- γ).  Also as a result of secretion of IFN- 
γ, B cells undergo isotype switching to produce IgG2a.  IL-2 and IFN- γ encourage CD8+ 
T cells to grow and become cytotoxic T cells.  IFN- γ will also stimulate B cells to 
initiate complement and the opsonization of a foreign antigen to be phagocytosed.  Th1 
cells also activate macrophages to internalize antigen, undergo cell-mediated toxicity, and 
delayed-type hypersensitivity [58]. 
       Activation and differentiation of B cells and eosinophils is stimulated by Th2 T cells 
by the secretion of IL-5, as well as B cell isotype switching.  These Th2 cells secrete IL-4 
which stimulates B cells to produce IgG1 and promote the growth and survival of T cells.  
Once the B cells have matured, IL-10 increases expansion of MHC class II molecules on 
the B cells as well as inhibits cytokine release from macrophages.  The Th2 cytokines IL-
4 and IL-13 are responsible for the alternative activation of macrophages [64].   
       The CD8+ family of T cells differentiate into cytotoxic T cells in response to IL-2 for 
the destruction of antigen-MHC class I complexes.  These T cells secrete IFN-γ, TNF-β, 
and TNF-α to activate macrophages.  They are also responsible for inhibiting pathogens 
by increasing expression of MHC class I molecules on macrophages by the secretion of 
IFN- γ.   The CD8+ T cells may trigger cell apoptosis by expressing Fas ligand or by 
releasing lytic granules, such as perfornin to form pores in the target cell’s membrane 
[58]. 
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       It is now thought that dendritic cells and complement are the bridge between innate 
and adaptive immunity [65,66].  Dendritic cells are special macrophages, unique in their 
ability to stimulate naïve T cells. Originally hematopoietic stem cells in the bone marrow, 
immature dendritic cells migrate through blood to non-lymphoid tissues when guided by 
chemokines.  While immature, they reside in peripheral tissues and capture and process 
any antigen they receive.  When stimulated by inflammatory signals produced by 
pathogens or danger signals, they mature and migrate to the lymph nodes where they 
present antigen for T cell priming (Figure 2-1, Figure 2-2).   
       Direct contact with a biomaterial is also a maturation stimulus for dendritic cells. 
Dendritic cells treated with PLGA films or PLGA MP show moderate levels of dendritic 
cell maturation as compared to the potent dendritic cell maturation activator, LPS. Films 
and microparticles made of PLGA were also found to moderately increase expression of 
co-stimulatory and MHC class II molecules [67].  Much research focuses on DC 
maturation in order to find a method to suppress their maturation with a view towards not 
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 Antibody-mediated adaptive immunity is responsible for rejection of implants 
containing foreign antigen such as xenogenic or allogeneic tissues.  Current interest lies 
in methods to induce tolerance such as by deletion of T cells, as in mixed bone chimeras, 
or by costimulatory blockade or APC depletion so that T cells are not able to respond to 
an antigen.  The adaptive immune response towards xenogenic tissue is mediated largely 
by CD4+ T cells via the indirect pathway of antigen presentation (Figure 2-1).  Dendritic 
cells may also be manipulated to induce tolerance.  For example, blocking the second 
signal pathway of antigen presentation by anti-CD28, anti-B7, anti-CD40, anti-CD40L, 
and CTLA4-Ig may reduce the activity of antigen presenting cells [65].   
 A biomaterial, as an adjuvant, may boost the immune response, stimulating the 
humoral and cell-mediated immune responses (Figure 2-3).  A strong adjuvant, Complete 
Freund’s adjuvant (CFA) induces a high immune response to co-delivered foreign 
antigen.  There is a great advantage in using a biomaterial with an antigen in a vaccine to 
boost the immunogeneicity of protein or DNA vaccines which induce low T and B cell 
mediated adaptive immune response.  Adjuvants also may contain heat inactivated 
microbacterial particles which activate and mature dendritic cells to produce cytokines 
and a phenotype with stable expression of MHC and costimulatory molecules to support 

































The ‘Danger’ Model of Adaptive Immunity  
 
           Dendritic cells are not only stimulated to act as antigen-presenting cells after 
exposure to exogenous pathogens as described above, but may in fact become mature 
upon ligating endogenous proteins called ‘danger signals’ which are released from 
stressed, damaged, or dying cells (Figure 2-2).  Such endogenous proteins are cell and 
tissue derived endogenous ligands which include heat-shock proteins, necrotic cells and 
extracellular-matrix breakdown products [68].  Specifically, hyaluronan fragments and 
heparin sulfate proteoglycan [69] will bind to TLRs on DCs to result in NF-κB 
activation, which regulates many proinflammatory and immune regulatory genes 
resulting in dendritic cell maturation [70,71,72].  Also, proteins which adsorb to 
biomaterials such as fibrinogen [73] and fibronectin [74] bind to TLRs on DCs, 
mediating an adaptive immune response.  Stressed and necrotic epithelial cells will 
activate human eosinophils [75]. The ‘danger’ model of immunity, which was proposed 
in 1994, suggests that only an association between an antigen and a ‘danger signal’ will 
trigger adaptive immunity after the recognition of these endogenous proteins by TLRs 
[68, 69].  
The human 60-kDa heat-shock protein (HSP60) is a danger signal to the innate 
immune system, stimulating APCs.  Macrophages will respond to HSP60 via the release 
of TNF-α depending on the dosage of HSP60 present [76].  Heat-shock protein 60 is also 
responsible for inducing gene expression of Th1 cytokines IL-12 and IL-15, suggesting it 
plays a role in expression of Th1 tissue inflammation [76].  Different HSPs may have 
different capacities to activate APCs.  For example, HSP60 induces DC maturation and 
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activation to produce proinflammatory cytokines while HSP71 comparatively is a weak 
inducer of DC maturation [77].   
  Uric acid is a well known endogenous danger signal which cells may release 
during injury.  It can stimulate dendritic cells to mature and initiates the activation of 
cytotoxic T helper cells when co-injected with antigen.  If uric acid is removed, the 
immune response towards antigens associated with injured cells is inhibited.  This 
suggests a link between cellular injury and the immune response towards injured and 
dying cells.  This uric acid is a product of the degradation of RNA and DNA into purines 
in injured cells [78].  Understanding the mechanisms of activating dendritic cells by such 
endogenous ‘danger signals’ may lead to a better understanding of transplant rejection 
and immune responses to tissue engineered constructs which are often implanted into a 
tissue site, resulting in cell stress, inflammation and tissue damage [79,80,81]. 
 
Immune Responses in Tissue Engineering 
 
 
During biomaterial implantation, a non-specific inflammatory response is initiated 
including aspects of protein adsorption, complement activation, coagulation, and 
neutrophil and macrophage adhesion and activation [82].  In addition to this 
inflammatory response, transplanted cells (particularly if they are allogenic or xenogenic) 
seeded into a biomaterial will be recognized as foreign by the host, inducing an antigen-
specific immune response [82].  Encapsulated cells may shed antigens, which are able to 
pass through the biomaterial capsule and are then internalized, processed and presented in 
association with the host MHC class II molecules by APCs to host CD4+ helper T cells 
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in the indirect pathway of antigen recognition [82] (see Figure 2-1).  Although polymer 
membranes are to provide immunoisolation of transplanted cells, these shed antigens are 
able to stimulate the immune system which can lead to the destruction of the 
encapsulated cells [82].  The biomaterial component of the tissue engineering device also 
acts as an adjuvant, enhancing the humoral immune response towards a specific antigen.  
For example, the model shed antigen, ovalbumin (OVA), adsorbed to different 
biomaterial carriers in the form of microparticles or scaffolds formed a moderate immune 
response as compared to the polymer or protein alone [83].   
  Xenografts pose the greatest risk of an immune response.  However, reconstituted 
extracellular matrix proteins have been used for vascular tissue, abdominal wall tissue, 
and ligament tissue after modifications.  Porcine small intestinal submucosa (SIS) is an 
acellular extracellular matrix which is used for tissue repair in many species.  The SIS 
does cause an acute inflammatory response with IL-4 and IL-10 expressed at the graft site 
and eventual tissue remodeling.  Anti-SIS antibodies were also produced, which were 
restricted to the IgG1 isotype [84].  This immune response suggests that SIS is 
immunogenic, but Th2 restricted which suggests that the biomaterial will be accepted.   
All biomaterials with time become surrounded by fibrous capsules, impeding 
interaction of the biomaterial with the surrounding host tissue [85].  Long-term tissue 
engineered constructs in the future will attempt to achieve reduced fibrous capsule 
formation, making tissue engineering devices more biocompatible and able to incorporate 


















 Male C57BL/6 mice (six to eight weeks old) (Charles Rivers Laboratory, 
Wilmington, MA) were allowed to acclimate to their new environment for one week prior 
to receiving the antigen-polymer vehicle combinations.  Mice were housed (six per cage 
with two cages per treatment type) in the Whitehead Center animal facility at Emory 
University.  Animal care and treatment were in compliance with the Institution Animal 













Polymeric Carrier Vehicles Preparation and Characterization 
 
 
Preparation of Polymeric Biomaterial Microparticles 
 
Poly(lactic-co-glycolic acid) microparticles (PLGA MP), coated with polyvinyl 
alcohol (PVA), were prepared using a double-emulsion solvent-extraction technique as 
previously described [86].  Briefly, 200 mg of 50:50 PLGA (MW = 125,000; 
Birmingham Polymers, Birmingham, AL) was dissolved in 1.8 ml dichloromethane 
(DCM) (Sigma, St. Louis, MO) on a shaker overnight.  An OVA (chicken egg, Grade VI, 
Sigma) solution with concentration of 100 µg/µl was prepared in 1 % (w/v) PVA (87-89 
% hydrolyzed, Avg MW=13,000-23,000; Sigma) in distilled/deionized water.  Under 
high-speed vortexing, 100 µl of the protein solution containing 10 or 0 mg (negative 
control) OVA was mixed with the PLGA/DCM solution for 1 minute to form the first 
emulsion.  This emulsion was then rapidly added to 50 ml of 1 % (w/v) PVA in 
distilled/deionized water with stirring at 1400 rpm.  After 5 minutes, 100 ml of 2 % (v/v) 
isopropanol (Sigma) in distilled/deionized water was added.  The mixture was then 
allowed to stir for an additional two hours during which time the DCM solvent 
evaporated.  The microparticles were collected by centrifugation in preweighed 
centrifuge tubes and then washed 5 times with 20 ml of sterile filtered distilled/deionized 
water, collecting between washes by centrifugation and resuspension in 2% (v/v) 
isopropanol solution.  The MPs were then washed with 2 % (v/v) isopropanol twice and 
sterile filtered distilled/deionized water three times.  After suspending the MP in sterile 
filtered distilled/deionized water they were placed under ultraviolet light in a laminar 
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flow hood for an hour for sterilization before injection. A Limulus Amebocyte Lysate 
endotoxin assay was preformed on the PLGA MPs, prepared as for injection, according 
to the manufacturer’s instructions (BioWhittaker, Walkersville, MD).  For 3.88 mg of 
PLGA MPs without incorporated OVA (as used for injection) the effective endotoxin 
content was 0.204 ± 0.2 EU/mL.  For 8.05 mg of PLGA MPs with incorporated OVA (as 
used for injection) the effective endotoxin content was 0.267 ± 0.1 EU/mL.  For MPs 
which would be injected into mice, air-drying was used instead of freeze-drying to 
decrease the amount of MP clumping, whereas, for protein quantification, MPs were 
freeze-dried.  Once dry, the total batch of PLGA MPs weighed 80 mg.  The mean size 
and standard deviation of the PLGA MP were obtained using a Coulter Multisizer II 
(Coulter Corporation, Miami, FL).  For the PLGA MP, sizes ranged from 3 to 20 µm with 
a mean diameter of 3.5 µm (Table 3-1).   
 
 
Preparation of PLGA Scaffolds 
 
The PLGA scaffolds (PLGA SC) were prepared by a salt-polymer casting 
particulate-leaching technique with NaCl as the leachable component [87,88].  Sodium 
chloride (Sigma) was sieved into particle size range using a sieve shaker (W.S. Tyler, 
Mentor, OH) and 355-425 µm NaCl particles were used as the leachable component.  
Briefly, 0.5 g of 50:50 PLGA (molecular weight of 125,000 Daltons) (Birmingham 
Polymers) was dissolved in 5 ml DCM and the polymer was allowed to completely 





Table 3-1  Treatment Groups and Physical and Chemical Properties of 
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DCM/OVA mixture was homogenized at 1,000 rpm for 1 minute using a PowerGen 700 
homogenizer (Fisher Scientific, Pittsburgh, PA).  The PLGA-DCM/OVA mixture was 
poured over the 4.5 g NaCl (355-425 nm) and pre-spread evenly in a 50 mm-diameter 
Teflon Petri dish (VWR, Bristol, CT) in a 9:1 salt ratio.  The mixture was stirred 
completely, covered, and placed in a fume hood overnight.  The cover was removed the 
next day and the dish left uncovered in the fume hood overnight to allow the DCM to 
evaporate.  The disks were then removed and placed in distilled/deionized water on a 
shaker to dissolve out the leachable component (NaCl), while refreshing the water every 
couple of hours.  The disks were kept in water overnight and then allowed to air dry on 
sterile pads in a laminar flow hood.  Once dry, 0.7 cm diameter and 0.2 cm thick SC were 
punched out of the disk using an ethanol-sterilized punch.  These SC (for either 
implantation or protein quantification) were then freeze-dried overnight using a freeze 
dryer (Labconco Incorporation, Kansas City, MO). The SCs were washed with 70 % 
ethanol three times and then sterile-filtered distilled/deionized water three times for 10 
minutes each on a shaker 24 hours before implantation.  The SC were placed on sterile 
pads under UV light in a laminar flow hood for 30 minutes per side before implantation.  
For PLGA SC (0.7 cm diameter, 0.2 cm thick) as used for implantation, the effective 
endotoxin contents were determined, using Limulus Amebocyte Lysate endotoxin assay 
(BioWhittaker), to be 0.015 ± 0.07 EU/mL and 0.055 ± 0.2 EU/mL for PLGA SC without 







Dry weights were determined for both PLGA SC and PLGA MP in pre-weighed 
cryovials (VWR).  The cryovials containing the polymers were flash frozen with liquid 
nitrogen and then lyophilized overnight using a freeze dryer (Freeze Dry 
System/Freezone 4.5, Labconco Incorporation, Kansas City, MO). Polymer weights were 
determined in triplicate and the mean weight and standard deviation were determined.   
 
Quantification of OVA Associated with PLGA SC and PLGA MP 
 
In the same manner as described above, PLGA disks were fabricated and freeze-
dried and then digested overnight, rotating at 37 °C in 44 ml 0.1 M NaOH with 5 % (w/v) 
sodium dodecyl sulfate (SDS) (Sigma).  The PLGA SC punched out of a whole disk were 
treated the same manner, but with a digest volume of 4 ml 0.1 M NaOH with 5 % (w/v) 
SDS. Two PLGA MP batches prepared simultaneously as described above were 
combined and then split in two halves.  Then one half was freeze dried (24 hours) and 
digested for determination of OVA incorporation.  The other half was used ‘fresh’ for 
injection into mice, the next day.  In this way, the actual amount of OVA associated with 
the polymer was determined for the sample which was then injected into mice.  This was 
necessary because of variability in the amount of OVA incorporation (even with the same 
starting amount of OVA) and given the constraint of keeping the OVA/polymer ratio the 
same for both the microparticle and scaffold forms. Lower variability in the incorporation 
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of OVA into scaffolds (as compared to microparticles) permitted such an approach.  
Freeze-dried MPs (80 mg) were digested with 15 ml 0.1 M NaOH and 5% SDS overnight 
at 37 °C.  The total protein contents of the digested PLGA SC and PLGA MP were then 
determined using the Bicinchoninic Acid (BCA) protein assay (Sigma) and used to 
determine the amount of OVA incorporated into each form considering the initial amount 
of OVA used during preparation.  The BCA assay was preformed according to the 
manufacturer’s instructions.   The samples were transferred to a cuvette and the 
absorbance values were read at 562 nm using an Ultraspec 4300 UV/Visible 
Spectrophotometer (Amersham Pharmacia, Cambridge, England).  Samples were read in 
triplicate, the concentrations determined using the standard curve and the means 
calculated.  Using these concentrations, the actual OVA amount incorporated into the 
PLGA MPs or SC was determined.  A constant ratio of amount of OVA to amount of 
polymer (OVA/polymer ratio) was determined to be 1.075 mg OVA/mg PLGA for both 
PLGA MP and PLGA SC (Table 3-1).  The percent OVA incorporation was 36.50% for 
PLGA SC and 20% for PLGA MP (Table 3-1). 
 
Humoral Immune Response Assay 
 
Co-Delivery of OVA with PLGA MP and PLGA SC in Mice 
 
The treatment groups for mice are summarized in Table 3-1 with the amounts of 
OVA and polymer delivered indicated for each.  Prior to murine implantation, SC with 
OVA and SC without OVA were placed under UV light in a laminar flow hood for 30 
minutes per side and then added to sterile PBS.  Scaffolds with incorporated OVA 
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weighed approximately 8.75 mg, whereas PLGA SC without incorporated OVA weighed 
4 mg.  Prior to murine injection, MP were centrifuged (260 g, 5 minutes) and 8.05 mg of 
air-dried PLGA MP with incorporated OVA or 3.88 mg PLGA MPs without OVA were 
resuspended in 100 µl PBS.  These weights corresponded to approximately 2.69 x 105  
microparticles.  For either the MP or SC form, the OVA/polymer ratio was the same at a 
value of 1.075 mg OVA/mg polymer (determined and set as described above) and the 
amount of polymer delivered for either form was constant at 3.88 mg and the amount of 
OVA was constant at 4.17 mg (or 0 mg as a control).  
C57BL/6 mice were given 100 µl dorsal subcutaneous injections of MP with or 
without OVA.  Other C57BL/6 mice were given a dorsal subcutaneous implantation of 
SC with or without OVA under sterile surgical conditions.  Immunization with PBS with 
(4.17 mg OVA in 100 µl PBS) and without OVA served as negative controls and 
immunization with (8.34 mg OVA in 50 µl PBS) or without OVA in PBS in a 1:1 
dilution with Complete Freund’s Adjuvant (CFA) (Sigma) served as the positive controls.  
Three weeks after primary immunization, all mice except for those in the CFA group, 
received a booster of an OVA solution in PBS at the same concentration of 4.17 mg OVA 
in 100 µl PBS into the injection/implantation site (no additional polymer was delivered).  
For the positive control, CFA group, Incomplete Freund’s Adjuvant (IFA) (Sigma) was 
injected instead of CFA to prevent a potential lethal dosage of CFA.  Six mice were 
placed in each treatment or control group.   
Blood samples were collected from the retro-orbital plexus of the mice at 2, 3 
(prior to boosting), 4, 8, 12, and 18 weeks after the primary immunization.  The bleeds 
clotted overnight at 4 °C and the serum was removed after centrifugation at 2300 g for 10 
 42
minutes.  Serum was stored at –20 °C until analysis for anti-OVA IgG antibodies and 
isotypes (IgG1, IgG2a) by ELISA.   
 
Quantification of Anti-OVA IgG and Isotypes by ELISA 
 
The production of anti-OVA total IgG and the isotypes, IgG1 and IgG2a, in 
mouse serum samples was measured by ELISA as previously described [83]. Standard 
wells of Nunc ImmunoTM MaxiSorp ELISA plates (Life Technologies, Paisley, UK) were 
coated with a 1 µg/ml solution of goat anti-mouse IgG, IgG1, or IgG2a (Southern 
Biotechnology Associates, Birmingham, AL) in 0.1 M sodium bicarbonate (NaHCO3) 
(pH 9.5).  Sample wells of the plate were coated with a 40 µg/ml solution of OVA in 0.1 
M NaHCO3.  After incubation overnight at 4 °C, the plates were washed four times with 
0.5 % (v/v) Tween 20 in PBS (PBT) and blocked with 5 % (w/v) condensed milk in PBT 
(PBT-CM) for 2 hours at 37 °C.  After washing the plates 4 times with PBT, triplicates of 
each serum sample were diluted 1/100 or 1/1000 in PBT-CM and added to the sample 
wells.  The standard wells received mouse IgG, IgG1, or IgG2a standard diluted 1:1 in 
PBT-CM starting at 1 µg/ml to a final concentration of 0.488 ng/ml, each concentration 
in duplicate.  The plates were allowed to incubate at 37 °C for 2 hours and then washed 
four times with PBT and incubated at 37 °C for 2 more hours with a 1:1000 dilution of 
alkaline phosphatase-conjugated goat anti-mouse IgG, IgG1, or IgG2a (Southern 
Biotechnology Associates) in PBT-CM.  After four washes with PBT, the reaction was 
developed using a p-nitrophenyl phosphate solution prepared from tablets dissolved in 1 
X diethanolamine buffer prepared from an alkaline phosphate substrate kit (Bio-Rad, 
Hercules, CA).  The reaction was stopped after 2 minutes by adding 0.4 M sodium 
 43
hydroxide (NaOH) and the absorbance values were read at 405 nm using a 
Powerwavex340 ELISA plate reader.  The mean absorbance was calculated for each set 
of triplicate serum samples and the mean concentration and standard deviation for each 
sample was determined using a standard curve.     
 
In Vitro OVA Protein Release Kinetics From PLGA SC and PLGA MP 
 
The in vitro OVA protein release kinetics from PLGA SC and PLGA MP were 
determined as previously described [86,89].  To keep the polymer amount constant 
between the two different carriers, 40 mg PLGA MP (with and without OVA) were 
suspended in 15 ml sterile PBS in a glass vial (VWR) and 40 mg PLGA SC (5 small SC, 
with and without OVA) were suspended in 15 ml sterile PBS; each sample in duplicate 
vials. These glass vials were then incubated at 37 °C on a rotating shaker.  At various 
time intervals, day 1, 4, 7, 14, 21, and 28, the vials were centrifuged and the supernatant 
was removed and stored at –20 °C until total protein analysis using a BCA assay.  Fresh 
15 ml sterile PBS was added to each vial and the release experiment continued.  In 
preparation for the BCA protein assay, the protein samples were concentrated using 
Centricon Plus-20 centrifugal filter devices (Millipore Incorporation, Billerica, MA), per 
manufacturer’s instructions.  Briefly, the 15 ml protein solution was added to the sample 
filter cup and centrifuged for 10 minutes at 2,000 g.  Flow collected in the filtrate 
collection tube was discarded and the filter unit was inverted to sit on a retentate cup and 
centrifuged at 1,000 g for 2 minutes to collect approximately 3 mL of concentrated OVA 
solution in PBS.  All concentrated samples were analyzed on the same day using the 





Statistical analysis was preformed using an ANOVA general linear model with 
Minitab software (Version 13, Minitab Inc., State College, PA).  p-values of ≤ 0.05 were 






























Preparation of Polymeric Biomaterial Microparticles 
 
The 50/50 PLGA MP were fabricated using a double-emulsion solvent-extraction 
technique.  The resulting microparticles had a size range from 3-20 µm and a mean 
diameter of 3.5 µm (Table 3-1).  Figure 4-1 shows a representative size distribution of the 
50/50 PLGA MP. 
 
 
Polymer and Protein Quantification 
 
 For both the PLGA MP and the PLGA SC the same OVA/polymer ratio of 1.075 
mg OVA/mg polymer was delivered in vivo.  To keep the same amount of polymer and 
protein between the two types of polymeric carriers, MP were centrifuged and 8.05 mg of 
air-dried PLGA MP with incorporated OVA or 3.88 mg PLGA MPs without OVA were 
resuspended in 100 µl PBS.  These weights corresponded to approximately 2.69 x 105  
microparticles. The PLGA MP had a percent incorporation of OVA of approximately 
20% while the PLGA SC had a percent incorporation of OVA of approximately 36.50%. 
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Each PLGA SC with incorporated OVA weighed approximately 8.75 mg (PLGA SC 























































In Vitro Protein Release Kinetics 
 
 
In vitro release kinetics of OVA into PBS from OVA-loaded PLGA MP and 
PLGA SC were evaluated over 28 days.  For both carriers, 40 mg of polymer was 
incubated in PBS to keep the polymer amount consistent and each carrier incubated 
contained the same OVA/polymer ratio (1.075 mg OVA/mg polymer).  The PLGA MPs 
and PLGA SCs remained intact over the 28 day protein release experiment although there 
was some loss of mechanical properties for the PLGA SC over this time period.  The 
overall release rates of OVA from the polymer carriers were similar for both PLGA SC 
and PLGA MP (Figure 4-2).  The release rate was determined by the ratio of amount of 
OVA released at each time point to the amount of polymer incubated over the 28 days of 
the experiment. Each data point indicates the amount of OVA released per 40 mg 
polymer during the period concerned between consecutive time points  (Figure 4-2, Mean 
± S.D.; n=2 independent samples; m= 3 determinations). 
The release rates of OVA from PLGA SC and PLGA MP at day one were the 
same with a release of 6.44 mg OVA/24 hours.  Thereafter, the release rates for the rest 
of the first week were similar at 2 mg/day for both carriers.  For the remainder of the 
experiment, the release rates were also similar at 1 mg/day.  The total amount of OVA 
released from the PLGA MP over the 28 days of the experiment was 43 mg (100%).  
Forty milligrams (93%) of OVA was released from the PLGA SC over the 28 days of the 
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Table 4-1  Cumulative Release of OVA from PLGA SC and PLGA MP 
during in vitro Protein Release Kinetics 
100%43 mg1.075 mg OVA/mg 
Polymer
PLGA MP with OVA
93%40 mg1.075 mg OVA/mg 
Polymer
PLGA SC with OVA
% OVA lostAmount of OVA lost 
over 28 days total


















         The production of anti-OVA total IgG and the isotypes, IgG1 and IgG2a, in mouse 
serum samples was measured by ELISAs to assess the humoral immune response to 
OVA released from PLGA MP and PLGA SC as compared to appropriate controls.  
Polymeric scaffolds and polymeric microparticles delivered without OVA did not result 
in anti-OVA IgG antibody production being statistically different from the antibody 
levels observed for the negative control, PBS without OVA (Figure 4-3, Mean ± S.D.; 
n=4-6 mice; note the ordinate is in log scale).    At a few time points CFA without OVA 
did produce moderate levels of anti-OVA IgG, in contrast with the PLGA SC and PLGA 
MP (Figure 4-3). Ovalbumin delivered with PBS (negative control) into C57BL6 mice 
resulted in low baseline levels of anti-OVA IgG antibody production while OVA co-
delivered with CFA (positive control) elicited an intense humoral immune response 
characterized by high levels of anti-OVA IgG (Figure 4-4, Mean ± S.D.; n=4-6 mice; 
note the ordinate is in log scale.  * represents significant different from PBS, + represents 
significant difference from CFA).  Controlled release of OVA from PLGA SC resulted in 
high, sustained levels of OVA-specific IgG for the 18 week duration of the experiment 
(Figure 4-4).  For this polymeric vehicle, these levels of OVA-specific IgG were not 
statistically different from the positive control of OVA delivered in CFA, while being 
statistically different from the low baseline levels observed for the negative control of 
OVA delivered in PBS alone.  In contrast, OVA released from PLGA MPs induced 
transient, moderate levels of anti-OVA IgG which peaked at 3 weeks and tapered off 
thereafter to be at background levels by 12 weeks.  These levels of anti-OVA IgG were 
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statistically different from those observed for OVA delivered in PBS at 3 and 8 weeks 
(boost given at 3 weeks) but at all time points, the levels were statistically different from 






















































Figure 4-3 PLGA SC and PLGA MP without OVA do not produce IgG 













































+ + + +
 
Figure 4-4  Anti-OVA IgG (ng/ml) production for PLGA SC and PLGA MP 
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To assess the predominance of a Th1 versus a Th2 helper T cell response in the 
humoral immune response to OVA delivered with the two forms of polymeric carrier 
vehicles, the IgG isotypes were determined.  The IgG2a isotype is characteristic of a Th1 
response, whereas the IgG1 isotype is characteristic of a Th2 response.  Again, the 
polymeric carriers without OVA did not produce IgG1 (Figure 4-5, Mean ± S.D.; n=4-6 
mice; note the ordinate is in log scale) or IgG2a (Figure 4-6, Mean ± S.D.; n=4-6 mice; 
note the ordinate is in log scale) antibody levels significantly different from that of PBS.  
The generation of anti-OVA IgG1 antibodies in response to OVA co-delivered with each 
polymeric vehicle and controls (Figure 4-7, Mean ± S.D.; n=4-6 mice; note the ordinate 
is in log scale.  * represents significant different from PBS, + represents significant 
difference from CFA) showed similar trends to those observed for total anti-OVA IgG 
(Figure 4-4).  The levels of OVA-specific IgG1 for OVA released from PLGA SC were 
not statistically different from the levels observed for the positive control of OVA 
delivered with CFA (Figure 4-7).  Furthermore, the levels of OVA-specific IgG1 for 
OVA released from PLGA MP were significantly different from PBS only just after the 3 
week boost at 4 weeks (Figure 4-7).  There were some differences in the times at which 
the levels of IgG or IgG1 antibody levels peaked for the responses to OVA delivered with 
PLGA MPs.  Specifically, the anti-OVA IgG levels peaked earlier at week 3 while the 
anti-OVA IgG1 levels lagged with the peak at a later time point, week 4 (Figure 4-4 and 
Figure 4-7). Significant levels of anti-OVA IgG2a were observed for OVA released from 
PLGA SC at the time points between 4 and 12 weeks or delivered with the positive 
control, CFA, at the time points between 3 and 12 weeks, as compared to the low 
baseline levels observed for OVA delivered with PBS alone (Figure 4-8, Mean ± S.D.; 
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n=4-6 mice; note the ordinate is in log scale.  * represents significant different from PBS, 
+ represents significant difference from CFA).  Controlled release of OVA from PLGA 
MPs did not induce anti-OVA IgG2a at any time point (Figure 4-8).  Anti-OVA IgG2a 
levels were not detected at the 2 and 18 week time points for any of the carriers tested.  
The IgG1 levels (Figure 4-7) were slightly higher for CFA and PLGA SC than the IgG2a 
levels (Figure 4-8).  These results suggest the predominance of IgG1 isotype, although 














































Figure 4-5  PLGA SC and PLGA MP without OVA do not produce IgG1  
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Figure 4-6 PLGA SC and PLGA MP without OVA do not produce IgG2a    





















































Figure 4-7 Anti-OVA IgG1 (ng/ml) production for PLGA SC and PLGA MP     












































Figure 4-8 Anti-OVA IgG2a (ng/ml) production for PLGA SC and PLGA     














The biomaterial component of a tissue engineered device acts as an adjuvant in 
mediating an immune response to co-delivered antigen.  Polymeric vehicles without 
incorporated antigen in the form of scaffold or microparticles did not induce an immune 
response, indicating that the biomaterial alone does not induce an antigen-specific 
antibody response.  In addition, the biomaterial chemistry does not seem to have a 
significant influence on the immune response, at least with the limited materials tested in 
a previous experiment [83].  In this research, the extent of the enhancement of the 
antigen-specific antibody response towards incorporated OVA depended on the form of 
the polymeric vehicle carrier, either as a scaffold or a microparticle.    
The humoral immune response towards OVA controlled released from PLGA SC 
was sustained for the duration of the experiment at a high level, and not significantly 
different than that of OVA delivered with the positive control of CFA.  When the same 
amount of polymer and antigen was delivered and released at the same rate from PLGA 
MPs, the level of the humoral immune response was transient and at a moderate level as 
compared to SC and CFA.  These results indicate that PLGA in the form of a SC acted as 
a stronger adjuvant in the enhancement of the immune response toward incorporated 
antigen than PLGA in the form of MPs.  It should be noted that PLGA MPs did produce 
some moderate adjuvanticity.   
The immune response induced by the PLGA MP and PLGA SC with incorporated 
OVA was dominated by a Th2-type immune response as indicated by the production of 
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IgG1 antigen-specific antibodies.  This suggests that adjuvanticity of the biomaterial 
results in the activation of CD4+ T cells and the proliferation of isotype switching of B 
cells.  However, for CFA and PLGA SC carriers, anti-OVA IgG2a isotype levels were 
also significant, potentially indicating both a Th2 and Th1 response.  In previous research 
it was discovered that the immune response elicited by both MP and SC carriers with 
adsorbed OVA versus incorporated OVA were dominated by a Th2-type immune 
response as indicated by the production of OVA-specific IgG1 [83].  However, it has also 
been shown that PLGA MPs with adsorbed OVA were able to elicit a delayed type 
hypersensitivity (DTH) reaction in mice, which is a Th1-dependent response [67].  The 
mechanism by which PLGA contributes to the activation of T cells is through its adjuvant 
effect with the maturation of DCs upon biomaterial contact into efficient antigen 
presenting cells in vivo for the presentation of co-delivered OVA to prime T lymphocytes 
[67].  Other studies have confirmed an adjuvant effect of biomaterials to polarize Th 
response with varying results. Allergen-loaded PLGA MP can stimulated a Th2 response 
[90], Brucella ovis bacteria antigens encapsulated in poly-epsiloncaprolactone (PEC) MP 
further enhanced the already Th1 response to the unencapsulated antigen whereas PLGA 
MP encapsulation induced a Th2 response [91], and OVA encapsulated in PLGA MPs 
elicited a Th1 response [92].  The disparity between these results may be due to the 
differences in the type and form of the antigen used (peptide vs protein vs allergen), the 
mode of antigen co-delivery (encapsulated vs adsorbed), and the method of determining 
the nature of the Th response (serum IgG isotypes levels vs cytokines secreted by in vivo 
primed lymphocytes following in vitro second challenge with antigen vs DTH response).   
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To facilitate a distinction of the enhancement of the humoral immune response 
based on the polymeric vehicle form, OVA was incorporated into PLGA in the form of 
SCs or MPs for controlled release at the same rate with a constant amount of polymer and 
antigen delivered at a constant OVA/polymer ratio for these two carrier forms.  In this 
way, the key difference between the two carrier vehicle forms was the means by which 
the polymeric vehicle was introduced into the host.  The scaffolds, because of their size, 
required invasive surgical implantation, with associated tissue damage whereas the 
microparticles were minimally invasively delivered by injection.  
In a previous experiment [83], polymeric carriers of both microparticle and 
scaffold form were soaked in OVA concentrations of 1 mg OVA/ 1 ml PBS.  The OVA 
adsorbed to the surface of the polymeric carriers and its release was not controlled.  In 
this current study, a greater OVA concentration was used with 1.075 mg OVA/mg 
polymer and this OVA was incorporated into the microparticles via a double emulsion 
technique with a PVA coat and into scaffolds via homogenizing.  Keeping the same 
amount of OVA:polymer delivered constant as well as the amounts of OVA and polymer 
delivered allowed for determinations of the differences in the immune response between 
the two forms of carriers.   
 In the innate response, DCs may be activated in the absence of foreign pathogens 
through endogenous ‘danger signals’ from necrotic or stressed cells, or released from 
damaged or inflamed tissue. In the context of biomaterials and tissue engineering, 
‘danger signals’ could result from surgical implantation of a biomaterial or construct or 
other stress or necrosis of cells or inflammation caused by the presence of a foreign 
material. The TLRs recognize endogenous ligands which are relevant in the innate 
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response to biomaterials and have a significant role in the maturation of DCs.  Therefore, 
maturation of DCs in the context of implanted biomaterials would support their 
maturation to become efficient antigen presenting cells with an enhancement of the 
immune response towards associated antigen. 
The implantation of the PLGA SCs undoubtedly caused tissue damage with 
associated necrosis and inflammation.  In contrast, injection of PLGA MPs was a 
minimally invasive means of delivery.  In the innate response, DCs can be activated in 
the absence of foreign pathogens through endogenous ‘danger signals’ from necrotic or 
stressed cells, or released from damage or inflamed tissue [68, 69, 70].  These molecular 
danger signal are cell and tissue derived endogenous ligands such as heat shock proteins, 
small hyaluronan fragments, and heparin sulfate proteoglycan [71], or even proteins 
which adsorb to biomaterials such as fibrinogen [73], fibronectin [74] which bind to 
TLRs on DCs mediating their maturation to be efficient at stimulating T cells for an 
adaptive immune response.  The danger hypothesis states that an immune response only 
occurs if the antigen is presented along with ‘danger signals’ from stressed or necrotic 
cells or with associated tissue damage [70].  In the context of biomaterials and tissue 
engineering, ‘danger signals’ could result from surgical implantation of a biomaterial or 
construct or other stress or necrosis of cells or inflammation caused by the presence of a 
foreign material. The TLRs recognize endogenous ligands which are relevant in the 
innate response to biomaterials and have a significant role in the maturation of DCs.  
Therefore, maturation of DCs in the context of implanted biomaterials would support 
their maturation to become efficient antigen presenting cells with an enhancement of the 
immune response towards associated antigen, with the biomaterial acting as an adjuvant.   
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The results presented herein indicate the significant consideration of delivering a 
tissue engineered construct as non-invasively as possible to minimize any potential 
immune responses.  Furthermore, there is the potential to ‘hide’ an immunological tissue 
engineered construct if it is delivered as non-invasively as possible to avoid the 
generation of ‘danger signals’.  Experimental evaluation of the implantation environment 
for the molecular basis for biomaterial and tissue engineered construct associated ‘danger 
signals’ remains to be elucidated.   
To further strengthen the biomaterial implantation associated ‘danger signals’ 
explanation for the results herein, other possible explanations and contributions can be 
ruled out.  The in vitro protein release experiment demonstrated similar OVA release 
kinetics for both the PLGA SC and PLGA MP over the 28-day duration of this study.  
This was evident even though the method used to prepare the PLGA MPs, coating with 
PVA, has been shown to result in an initial burst of release and a faster release rate of 
protein due to its hydrophilic nature as compared to uncoated PLGA MPs with no effect 
on the bioactivity of the released protein [86].  A possible difficulty with the 
incorporation of OVA into PLGA SCs was the salt leaching step during which protein 
may be released.  However, this was taken into account by determining protein 
incorporation into the PLGA SCs after the salt leaching step and keeping the 
OVA/polymer ratio constant for both carrier vehicles.  Therefore, the stronger humoral 
immune response towards OVA released from PLGA SCs as compared to PLGA MPs 
was not due to a higher rate of OVA release from the PLGA SC carrier.  While there was 
a change in the mechanical properties of the PLGA SC over the 28 days of the 
experiment, becoming slightly more brittle, consistent with the observations of others 
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[93,94], this did not lead to changes in protein release kinetics in vitro.  Presumably, on a 
smaller scale, changes in the mechanical properties of the PLGA MPs were also 
occurring, but were not as readily observable.  Furthermore, these changes in mechanical 
properties are likely to also occur in vivo as the polymer degrades, but the PLGA MPs 
and PLGA SCs being of the same polymer, do not likely explain the differences in the 
humoral immune response to OVA released from these two carrier forms. 
The hydrophilic nature of the PVA coating on the MP will render it more 
biocompatible than that of PLGA presumably due to lower protein adsorption.  However, 
PVA is also highly water soluble and has been found to dissolve after 24 hours in water 
and is thought to dissolve  at a similar rate in vivo [83,95].  It is possible that this PVA 
coat minimized the PLGA adjuvant effect associated with PVA-coated PLGA MP than 
that associated with the PLGA SC.  Possible dissolution of the PVA coat may have 
contributed to a more significant immune response at later time points for the PLGA MP.  
However, the MP did induce only a transient response which was moderate and 
significantly less than that of PLGA SC and CFA, tapering off during the final weeks of 
the experiment.  After the expected time required for the PVA coat to dissolve, the PLGA 
MP still did not produce significantly high levels of anti-OVA IgG, IgG1, or IgG2a.   
Another difference between the two polymer carriers is their endotoxin levels.  
The OVA-loaded PLGA MP had an endotoxin level of 0.267 ± 0.1 EU/mL, much higher 
than that of the OVA-loaded PLGA SC at 0.055 ± 0.2 EU/mL.  The PLGA SC and PLGA 
MP had the same ratio of OVA:polymer.  Therefore this difference may be due to the 
higher surface area of the spherical PLGA MP, which is available for endotoxin exposure 
for detection.  It is possible that the PVA coat on the PLGA MP, which is exposed to the 
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environment, contains additional endotoxin levels, which therefore increases the 
endotoxin levels of the PVA-coated PLGA MP as compared to the PLGA SC.   
The protein release kinetics experiment demonstrated similar release kinetics for 
the PLGA SC and PLGA MP in vitro.  There is a concern of how these results will 
translate to the in vivo situation of antigen delivery from PLGA MP and PLGA SC as 
described herein for the resultant humoral immune response and the adjuvant effect of the 
biomaterials.  Presumably, host proteins will adsorb to the PLGA MPs and PLGA SCs in 
vivo which may alter the protein release profile from that measured in vitro.  If the effect 
of adsorbed host proteins was the same for both PLGA MPs and PLGA SCs, then the 
release profiles would be altered to the same extent for both carrier vehicles.  Performing 
the in vitro protein release experiments in PBS containing serum may more accurately 
approximate the in vivo situation.  The increased protein concentration in serum changes 
the dynamics of the experiment and may actually slow the release of OVA from 
polymeric carriers.  In vivo experiments for protein release kinetics are limited.  One of 
the complications is that proteins released from polymeric carriers, such as growth 
factors, may be cleared due to filtration, bind to receptors, or be enzymatically degraded.  
This may affect the biological efficacy of using such a protein-release system [96].  One 
possible complication with the in vitro release kinetics experiment presented herein is the 
compatibility of the digest reagents with the BCA assay.  Some detergents may interfere 
with absorbance readings, resulting in incorrect analysis.  This was avoided by using 5 % 
SDS as suggested by the manufacturer (Sigma) to be a compatible concentration of the 
detergent.   
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Another consideration which may have affected the enhancement of the immune 
response depending on the form of the polymeric carrier form is the actual surface area 
available for interaction with the host and for release of OVA.  For PLGA SC (as a non-
porous cylinder) the surface area was calculated to be 1.21cm2.  The total surface area for 
the PLGA MPs (2.69 x 105 microparticles of 3.5 µm diameter) which were injected 
(based on non-porous spheres) was calculated to be 1,035.11cm2.  Therefore, if any effect 
of surface area of the polymeric carriers was important, if did not translate into a higher 
release rate of incorporated antigen nor a greater adjuvant effect on the humoral immune 
































The higher level of humoral immune response observed for OVA delivered with 
PLGA SC implicates implantation associated 'danger signals' due to tissue damage in the 
enhancement of this immune response.  Evaluation of the implantation environment for 
the molecular basis for biomaterial and tissue engineered construct associated ‘danger 
signals’ are necessary to confirm this hypothesis. This might be done either by western 
blots of exudates for known danger signals or treatment of dendritic cells in vitro with 
biomaterial implant site exudates to assess the extent of DC maturation.  For example, 
PLGA MP with incorporated OVA may be delivered into a surgical cut, much like that of 
the PLGA SC with implantation, to determine if ‘danger signals’ released from the 
surgical cut are indeed enhancing the immune response towards PLGA SC.  
An issue to consider with the in vitro protein release kinetics is how it will 
translate to in vivo experiments where there are more dynamics, such as serum proteins 
and a constantly changing environment. It would also be best to find what is happening 
between time 0 and 24 hours during the protein release kinetics and consider how this 
would translate to release kinetics in vivo. 
The humoral immune response towards PLGA SC and PLGA MP was primarily 
Th2 helper T cell-dependent as exemplified by the predominance of IgG1 isotype, 
although for CFA and PLGA SC carriers, anti-OVA IgG2a isotype levels were also 
significant, potentially indicating both a Th2 and Th1 response respectively.  The results 
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presented herein indicate the significant consideration of delivering a tissue engineered 
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